Issued 2026-08-13 at $205.26 · now $202.00 (2026-08-13, −1.6% since)
Based on its own history, a month from the 2026-08-13 close, RVMD has typically landed between $164.27 and $267.83 — a range of −20.0% to +30.5% from the issuance price $205.26.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,612 overlapping 1 month windows · 2020-02-13 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($205.26) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where RVMD has typically landed a month from the 2026-08-13 close of $205.26 — the range is history, not a prediction.
- now $202 (-1.6%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $213.03 (+3.8%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $190.97–$235.1
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $164.27–$267.83
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-04-07 | −41.4% | −41.4% | +0.0% |
| 2020-03-03 | −40.7% | −40.7% | +2.9% |
| 2023-10-16 | −38.8% | −46.2% | +0.0% |
| 3 best | |||
| 2020-04-15 | +72.4% | +0.0% | +82.0% |
| 2020-04-17 | +61.3% | +0.0% | +65.0% |
| 2020-04-09 | +60.3% | −11.8% | +60.5% |
1,612 overlapping windows · 2020-02-13 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2027-05-15 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (source, as of 2026-08-14)
- 2027-05-31 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (source, as of 2026-08-14)
- June 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC (source, as of 2026-08-14)
- 2027-12-01 — Trial primary completion: Phase 3 primary completion: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) (source, as of 2026-08-14)
- June 2028 — Trial primary completion: Phase 3 primary completion: Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (source, as of 2026-08-14)
- December 2028 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors (source, as of 2026-08-14)
- 2028-12-30 — Trial primary completion: Phase 3 primary completion: Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) (source, as of 2026-08-14)
- May 2029 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors (source, as of 2026-08-14)
- 2029-05-10 — Trial primary completion: Phase 3 primary completion: Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~7 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.